New European study highlights differing priorities in physicians' therapy goals for advanced lung cancer patients

9 November 2016

Results from a survey analysing the prescribing behavior of 500 European physicians treating patients with advanced non-small cell lung cancer (NSCLC) have been released.

The research examined the primary therapy goal of physicians and their choice of treatment for patients with advanced adenocarcinoma of the lung, after first-line chemotherapy. An overview of the survey methodology and results can be viewed here. The physician prescribing behavior survey was sponsored by German family-owned pharma major Boehringer Ingelheim as part of its ongoing commitment to improving lung cancer care in an area of high unmet medical need.

Key results of the survey showed that:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK